Instrument Inactif

Gouvernance Theravance Inc Nasdaq

US88338T1043

Produits pharmaceutiques

Cours en clôture Nasdaq
- ^USD	-

28/09	CAC 40 : La Bourse de Paris devrait ouvrir en hausse, surveillant les taux et le pétrole	DJ
23/09	Innoviva, Inc. : Oppenheimer désormais positif sur le dossier	ZM

Comité Exécutif: Theravance Inc

Dirigeant

Fonctions occupéesDepuis

Pavel Raifeld

42 ans

Chief Executive Officer

20/05/2020

Marianne Zhen

57 ans

Comptroller/Controller/Auditor	01/02/2016
Corporate Secretary	29/12/2022

Stephen Basso

60 ans

Director of Finance/CFO

21/08/2023

Marcie Cain

Human Resources Officer

01/09/2023

Irwin Tendler

Investor Relations Contact	-
Public Communications Contact	-

Composition du Conseil d'Administration: Theravance Inc

Administrateur

ComitésDepuis

Jules Haimovitz

75 ans

Compensation Committee	12/02/2018
Governance Committee	12/02/2018
Nominating Committee	12/02/2018
Audit Committee Chair	12/02/2018
Governance Committee Chair
Nominating Committee Chair

Josephine Linden

74 ans

Audit Committee	18/05/2026
Compensation Committee	01/05/2018
Governance Committee	15/10/2014
Nominating Committee	01/05/2018
HR Committee	01/05/2018

Sarah Schlesinger

66 ans

Audit Committee	12/02/2018
Compensation Committee	12/02/2020
Governance Committee Chair	12/02/2020
Nominating Committee Chair	12/02/2020

Pavel Raifeld

42 ans

Director/Board Member

19/05/2025

Anciens Dirigeants et Administrateurs: Theravance Inc

Insider

Fonctions occupées

DepuisJusqu'au

George Abercrombie

Corporate Officer/Principal

20/06/2014

26/09/2018

Paul Pepe

Director/Board Member	01/06/2014	24/04/2018
Independent Dir/Board Member	01/06/2014	24/04/2018

Catherine Friedman

Director/Board Member	01/06/2014	24/04/2018
Independent Dir/Board Member	01/06/2014	24/04/2018

William H. Waltrip

Chairman	30/10/2014	01/04/2018
Independent Dir/Board Member	17/10/2011	01/04/2018

Michael Aguiar

Director/Board Member	15/08/2014	06/02/2018
Chief Executive Officer	15/08/2014	06/02/2018
Director of Finance/CFO	07/03/2005	09/10/2014
Investor Relations Contact	07/03/2005	-
President	07/03/2005	06/02/2018

Rick Winningham

Director/Board Member	03/05/2011	12/09/2011
Chief Executive Officer	01/10/2001	15/08/2014
Chairman	12/09/2011	30/10/2014
President	05/05/2014	15/08/2014

Kenneth R. Pitzer

Corporate Officer/Principal

25/03/2009

01/10/2014

Mathai Mammen

Chief Tech/Sci/R&D Officer	01/11/1996	30/09/2014
Founder	01/11/1996	30/09/2014

Leonard Blum

Corporate Officer/Principal

01/07/2007

30/09/2014

Bradford J. Shafer

General Counsel	01/08/1999	31/08/2014
Corporate Secretary	01/08/1999	31/08/2014

James Tyree

Director/Board Member	01/06/2014	-
Independent Dir/Board Member	01/06/2014	-

Renée Galá

Corporate Officer/Principal

01/06/2006

01/06/2014

Robert Gunderson

Director/Board Member	01/09/1999	01/06/2014
Independent Dir/Board Member	17/10/2011	01/06/2014

William Young

Director/Board Member	01/04/2001	01/06/2014
Independent Dir/Board Member	17/10/2011	01/06/2014

Arnold Levine

Director/Board Member	01/06/2003	22/05/2014
Independent Dir/Board Member	17/10/2011	22/05/2014
Director/Board Member	01/01/1996	01/02/2002

George Whitesides

Director/Board Member	01/11/1996	04/05/2014
Founder	01/11/1996	04/05/2014
Independent Dir/Board Member	17/10/2011	04/05/2014
Corporate Officer/Principal	01/11/1996	26/03/2009

Peter Ringrose

Director/Board Member	27/04/2010	04/05/2014
Independent Dir/Board Member	17/10/2011	04/05/2014

Henrietta Holsman Fore

Director/Board Member	25/10/2010	04/05/2014
Independent Dir/Board Member	17/10/2011	04/05/2014

Burt Malkiel

Director/Board Member	03/07/2007	04/05/2014
Independent Dir/Board Member	17/10/2011	04/05/2014

Frank Pasqualone

Chief Operating Officer

13/01/2014

Jeffrey Jonker

Corporate Officer/Principal

06/11/2013

David L. Brinkley

Corporate Officer/Principal

16/07/2009

01/07/2013

Jeffrey Finer

Corporate Officer/Principal

12/09/2011

Daniel M. Canafax

Chief Tech/Sci/R&D Officer

17/10/2011

P. Vagelos

Chairman	01/11/1996	27/04/2010
Founder	01/11/1996	27/04/2010

Carlos A. Parra

Corporate Officer/Principal

15/03/2010

Oranee T. Daniels

Chief Tech/Sci/R&D Officer

25/03/2009

Arthur Lee Campbell

Chief Tech/Sci/R&D Officer

01/06/2003

05/12/2008

Philip D. Worboys

Corporate Officer/Principal

25/03/2009

Michael M. Kitt

Corporate Officer/Principal

01/04/2002

20/06/2008

Craig Husfeld

Corporate Officer/Principal

01/01/2008

Dennis O. Driver

Human Resources Officer

01/10/2007

Eve Elizabeth Slater

Director/Board Member

08/12/2005

31/07/2007

Julian Baker

Director/Board Member

01/01/1999

25/04/2007

Ronn C. Loewenthal

Director/Board Member

25/04/2007

Nash Marinovich

Corporate Officer/Principal

01/01/2007

Joel A. Fernandes

Corporate Officer/Principal	01/01/2005	01/03/2006
Corporate Officer/Principal	-	-

Sue Dubman

Chief Tech/Sci/R&D Officer

01/01/2006

Heather Shane

Corporate Officer/Principal

17/10/2011

Michael R. Goldberg

Corporate Officer/Principal

01/09/2005

Alan Hopkins

Corporate Officer/Principal

15/03/2010

Marty Glick

Director of Finance/CFO

01/01/1998

01/01/2005

Samantha Miller

Corporate Officer/Principal

01/04/2002

Steven L. Barriere

Chief Tech/Sci/R&D Officer

25/03/2009

Rebecca Coleman

General Counsel

25/03/2009

Junning Lee

Chief Tech/Sci/R&D Officer

15/03/2010

Ted Love

Corporate Officer/Principal

01/02/1998

01/01/2001

Jeffrey A. Hagenah

Corporate Officer/Principal

01/04/2000

James Tananbaum

Chief Executive Officer	01/01/1997	01/01/2000
Founder	01/01/1997	01/01/2000

Jeffrey Drazan

Director/Board Member	01/12/1999	-
Independent Dir/Board Member	17/10/2011	-

Sharathchandra Hegde

Corporate Officer/Principal

01/09/1999

Michael F. Conner

Corporate Officer/Principal

01/01/1999

Edmund J. Moran

Chief Tech/Sci/R&D Officer	26/03/2009	-
Corporate Officer/Principal	01/02/1998	26/03/2009

Alex Sturmer

Corporate Officer/Principal

01/01/1998

Wesley D. Sterman

Director/Board Member	01/11/1996	-
Founder	01/11/1996	-

Kenneth L. Duchin

Corporate Officer/Principal

Mehdi Paborji

Corporate Officer/Principal

Petri T. Vainio

Director/Board Member

Allison Parker

Public Communications Contact

Cheryllyn de Ocampo

Public Communications Contact

Dimas Jiménez

Corporate Officer/Principal

Luis Peña

Corporate Officer/Principal

Joseph J. Tsiakals

Corporate Officer/Principal

William Polvino

Chief Tech/Sci/R&D Officer

Henry C. Settle

Corporate Officer/Principal

John Kent

Corporate Officer/Principal

19/03/2010

Mohammad Hirmand

Corporate Officer/Principal

Michael G. Mullen

Director/Board Member

John Hampton Griffin

Chief Tech/Sci/R&D Officer	-	-
Founder	12/01/2010	-

Donald E. Schmidt

Corporate Officer/Principal

J. Judice

Corporate Officer/Principal

Distribution de l'Âge des Dirigeants

Parité Homme Femme

Homme	5
Femme	3

Dont comité exécutif

Homme	3
Femme	2

Dont Administrateurs

Homme	3
Femme	1

Innoviva, Inc. est une société holding diversifiée disposant d'un portefeuille de redevances et d'autres actifs dans le domaine de la santé. Le portefeuille de redevances de la société comprend des actifs respiratoires développés en partenariat avec Glaxo Group Limited (GSK), notamment RELVAR/BREO ELLIPTA (furoate de fluticasone/vilanterol, FF/VI) et ANORO ELLIPTA (bromure d'uméclidinium/vilanterol, UMEC/VI). En vertu de l'accord de collaboration sur les agonistes bêta-2 à longue durée d'action (LABA), la société est en droit de percevoir des redevances de la part de GSK sur les ventes de RELVAR/BREO ELLIPTA. Les produits de la société comprennent GIAPREZA (angiotensine II), approuvé pour augmenter la pression artérielle chez les adultes atteints de choc septique ou d’autres formes de choc distributif, et XERAVA (éravacycline), approuvé pour le traitement des infections intra-abdominales compliquées chez l’adulte. Le troisième produit, XACDURO (anciennement connu sous le nom de sulbactam-durlobactam ou SUL-DUR), est approuvé pour le traitement des pneumonies nosocomiales et associées à la ventilation mécanique causées par Acinetobacter chez l’adulte. Le portefeuille de produits en développement comprend la zoliflodacine, un traitement expérimental de la gonorrhée non compliquée qui en est à la phase III des essais cliniques.

Employés

Secteur

Produits pharmaceutiques

Plus d'informations sur la société